- Home
- MRVL vs SNY Comparison
MRVL vs SNY Comparison
Compare MRVL & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRVL | SNY |
|---|---|---|
| Founded | 1995 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.0B | 110.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRVL | SNY |
|---|---|---|
| Price | $169.44 | $43.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 32 | 5 |
| Target Price | ★ $120.28 | $58.00 |
| AVG Volume (30 Days) | ★ 21.7M | 2.5M |
| Earning Date | 05-28-2026 | 04-23-2026 |
| Dividend Yield | 0.15% | ★ 3.47% |
| EPS Growth | ★ 400.98 | N/A |
| EPS | ★ 3.07 | N/A |
| Revenue | ★ $8,194,600,000.00 | N/A |
| Revenue This Year | $35.14 | $3.49 |
| Revenue Next Year | N/A | $6.10 |
| P/E Ratio | $52.30 | ★ $6.14 |
| Revenue Growth | ★ 42.09 | N/A |
| 52 Week Low | $58.62 | $43.10 |
| 52 Week High | $175.80 | $53.36 |
Technical Indicators
Market Signals| Indicator | MRVL | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 70.37 | 31.13 |
| Support Level | $73.93 | N/A |
| Resistance Level | $170.84 | $48.76 |
| Average True Range (ATR) | 8.95 | 0.70 |
| MACD | -0.82 | -0.45 |
| Stochastic Oscillator | 77.89 | 5.93 |
Price Performance
Historical ComparisonAbout MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.